ArticleOncotarget2016
Estrogen receptor-mediated miR-486-5p regulation of OLFM4 expression in ovarian cancer.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Unveiling novel transcriptomic prognostic biomarkers for specific breast cancer subtypes and treatment regimens.Pharmacological reports : PR · 2026Article
- RPSA-OLFM4 axis governs neutrophil migration against bacterial infection and sepsis.Nature communications · 2026Article
- Olfactomedin 4 in cancer development and progression.Biochimica et biophysica acta. Reviews on cancer · 2025Review
- Role of DNA methylation and non‑coding RNAs expression in pathogenesis, detection, prognosis, and therapy‑resistant ovarian carcinoma (Review).Molecular medicine reports · 2025Review
- Olaparib Combined with DDR Inhibitors Effectively Prevents EMT and Affects miRNA Regulation inInternational journal of molecular sciences · 2025Article
- Article
- Roles of microRNA-486-5p in the diagnosis and the association with clinical symptoms of cervical cancer.Biomarkers in medicine · 2024Article
- Comprehensive Analysis of Gene Expression Profiling to Explore Predictive Markers for Eradication Therapy Efficacy againstCancers · 2023Article
- Expression Profiles of Estrogen-Regulated MicroRNAs in Cancer Cells.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer.Bioscience reports · 2021Article
- Identification of the miRNA signature associated with survival in patients with ovarian cancer.Aging · 2021Article
- The Central Roles of Noncoding RNA in Estrogen-Dependent Female Reproductive System Tumors.International journal of endocrinology · 2021Review
- MicroRNA-486-5p Suppresses Lung CancerFrontiers in oncology · 2021Article
- Integrated microRNA and mRNA signatures associated with overall survival in epithelial ovarian cancer.PloS one · 2021Article
- miR-486 Promotes the Invasion and Cell Cycle Progression of Ovarian Cancer Cells by Targeting CADM1.Analytical cellular pathology (Amsterdam) · 2021Article
- Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer.Breast cancer research and treatment · 2020Article
- miRNA expression profile changes in the peripheral blood of monozygotic discordant twins for epithelial ovarian carcinoma: potential new biomarkers for early diagnosis and prognosis of ovarian carcinoma.Journal of ovarian research · 2020Article
- Perspectives on the Role of Non-Coding RNAs in the Regulation of Expression and Function of the Estrogen Receptor.Cancers · 2020Review
- The differential expression of miRNAs between ovarian endometrioma and endometriosis-associated ovarian cancer.Journal of ovarian research · 2020Article
- MicroRNA-486-5p and microRNA-486-3p: Multifaceted pleiotropic mediators in oncological and non-oncological conditions.Non-coding RNA research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Estrogen signaling influences the development and progression of ovarian tumors, but the underlying mechanisms are not well understood. In a previous study we demonstrated that impairment of estrogen receptor alpha (ERα)-mediated olfactomedin 4 (OLFM4) expression promotes the malignant progression of endometrioid adenocarcinoma, and we identified OLFM4 as a potential target of miR-486-5p. In this study we investigated the role of OLFM4 in ovarian serous adenocarcinoma. Ovarian serous adenocarcinoma tissues had reduced OLFM4 expression. Expression of OLFM4 was positively correlated with ERα expression, and estrogen (E2) treatment in ovarian cancer cells induced OLFM4 expression in an ERα-dependent manner. In contrast to ERα, miR-486-5p levels were inversely correlated with OLFM4 expression in ovarian serous adenocarcinoma. Ovarian cancer cells transfected with miR-486-5p mimics showed decreased OLFM4 mRNA expression, and ovarian cancer cells treated with E2 showed reduced cellular miR-486-5p levels. OLFM4 knockdown enhanced proliferation, migration, and invasion by ovarian cancer cells. Low expression of OLFM4 was also associated with high tumor FIGO stage and poor tumor differentiation. These results suggest OLFM4 is downregulated by miR-486-5p, which contributes to ovarian cancer tumorigenesis. Conversely, estrogen receptor signaling downregulates miR-486-5p and upregulates OLFM4 expression, slowing the development and progression of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.